Quintiles Transitional Holdings Inc. (NYSE:Q) insider Ari Bousbib sold 92,160 shares of the company’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $90.35, for a total value of $8,326,656.00. Following the sale, the insider now owns 1,082,919 shares of the company’s stock, valued at approximately $97,841,731.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Quintiles Transitional Holdings Inc. (NYSE Q) traded up 0.85% during trading on Monday, hitting $91.19. The stock had a trading volume of 1,055,896 shares. The stock’s 50 day moving average price is $89.50 and its 200-day moving average price is $82.85. Quintiles Transitional Holdings Inc. has a one year low of $70.10 and a one year high of $92.54. The stock has a market cap of $20.07 billion, a P/E ratio of 201.75 and a beta of 0.64.

Quintiles Transitional Holdings (NYSE:Q) last released its quarterly earnings data on Thursday, August 3rd. The medical research company reported $1.09 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.04. The business had revenue of $1.97 billion during the quarter, compared to analysts’ expectations of $1.96 billion. Quintiles Transitional Holdings had a net margin of 0.82% and a return on equity of 15.68%. The company’s revenue for the quarter was up 68.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.93 EPS. Analysts expect that Quintiles Transitional Holdings Inc. will post $4.57 earnings per share for the current fiscal year.

Quintiles Transitional Holdings announced that its board has initiated a stock buyback program on Wednesday, May 24th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical research company to repurchase up to 5.4% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s management believes its shares are undervalued.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Quintiles Transitional Holdings Inc. (NYSE:Q) Insider Sells 92,160 Shares of Stock” was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.dailypolitical.com/2017/08/07/insider-selling-quintiles-transitional-holdings-inc-nyseq-insider-sells-92160-shares-of-stock.html.

A number of analysts have weighed in on Q shares. Zacks Investment Research lowered Quintiles Transitional Holdings from a “hold” rating to a “sell” rating in a report on Wednesday, April 26th. Robert W. Baird upgraded Quintiles Transitional Holdings from an “underperform” rating to a “neutral” rating and upped their target price for the stock from $76.00 to $93.00 in a report on Friday, July 7th. Jefferies Group LLC upped their target price on Quintiles Transitional Holdings from $78.00 to $81.00 and gave the stock a “hold” rating in a report on Monday, May 15th. Evercore ISI restated an “in-line” rating and set a $88.50 target price (up previously from $84.00) on shares of Quintiles Transitional Holdings in a report on Thursday, May 4th. Finally, Credit Suisse Group restated an “outperform” rating and set a $96.00 target price (up previously from $94.00) on shares of Quintiles Transitional Holdings in a report on Tuesday, June 6th. Eleven analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Quintiles Transitional Holdings has a consensus rating of “Hold” and a consensus price target of $89.94.

Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Quintiles Transitional Holdings by 0.9% in the first quarter. Vanguard Group Inc. now owns 12,508,830 shares of the medical research company’s stock valued at $1,007,336,000 after buying an additional 113,613 shares during the period. Longview Partners Guernsey LTD boosted its stake in Quintiles Transitional Holdings by 6.2% in the second quarter. Longview Partners Guernsey LTD now owns 8,711,447 shares of the medical research company’s stock valued at $779,675,000 after buying an additional 505,526 shares during the period. Janus Capital Management LLC boosted its stake in Quintiles Transitional Holdings by 0.4% in the first quarter. Janus Capital Management LLC now owns 7,783,546 shares of the medical research company’s stock valued at $626,804,000 after buying an additional 27,675 shares during the period. BlackRock Inc. boosted its stake in Quintiles Transitional Holdings by 4,217.1% in the first quarter. BlackRock Inc. now owns 7,098,723 shares of the medical research company’s stock valued at $571,660,000 after buying an additional 6,934,290 shares during the period. Finally, State Street Corp boosted its stake in Quintiles Transitional Holdings by 2.6% in the first quarter. State Street Corp now owns 2,847,886 shares of the medical research company’s stock valued at $229,337,000 after buying an additional 71,563 shares during the period. 91.83% of the stock is owned by institutional investors and hedge funds.

About Quintiles Transitional Holdings

Quintiles IMS Holdings, Inc, formerly Quintiles Transnational Holdings Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Receive News & Ratings for Quintiles Transitional Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quintiles Transitional Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.